ERBB2 and breast cancer: In phase IIb, multicenter, randomized, single-blinded, controlled trial (NCT01570036), the efficacy of the combination with E-75 plus traustuzumab was evaluated in patients with HER2 low-expressing BC in the adjuvant setting.